Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490890 | 1.00 | PLA2G2A (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL8004701 | 0.92 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL8004697 | 0.92 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL3487439 | 0.91 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL3487433 | 0.91 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL18660379 | 0.87 | CASR (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL18660381 | 0.87 | CASR (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL17445655 | 0.87 | CASR (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL9851912 | 0.87 | PLA2G2A (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 | |
| SCHEMBL18660350 | 0.86 | ALDH1A1 (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | PLA2G2A 94/4885PLA2G10 304/4885PLA2G1B 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.